BTIG Keeps Their Buy Rating on Ovid Therapeutics (OVID)
BTIG's Thomas Shrader maintains a Buy rating on Ovid Therapeutics with a $4.00 price target, while Oppenheimer downgrades it to Buy with a $7.00 target. Ovid's shares closed at $1.20, with a consensus price target of $4.50, indicating a 275% upside. Shrader, a 3-star analyst, covers the Healthcare sector.
In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Ovid Therapeutics, with a price target of $4.00. The company’s shares closed yesterday at $1.20.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Shrader is a 3-star analyst with an average return of 2.6% and a 38.40% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Stoke Therapeutics, Harrow Health, and Gain Therapeutics.
Ovid Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $4.50, implying a 275.00% upside from current levels. In a report released yesterday, Oppenheimer also downgraded the stock to a Buy with a $7.00 price target.
